Based on recently published data from COG ANHL12P1, how will you use crizotinib in pediatric and AYA patients with ALK+ anaplastic large cell lymphoma?

I would discuss brentuximab (plus ALCL chemo backbone) with newly diagnosed ALCL with patients and families in the absence of any open trials. The published COG data looks favorable but hasn't been shown in a randomized setting to improve EFS/OS. With the VTE data (and the availability of Brentuxima...

I agree with Dr. @Dr. First Last, Brentuximab added to chemo produced the same outcome as Crizotinib added to chemo, without the thromboembolic issues.

Would go with the brentuximab combination if available.

MDD testing for NPM-ALK seems to be prognostic (as shown earlier by the European groups) eve...

I would agree with my colleagues that at the current time, I would favor using the brentuximab arm of ANHL12P1 due to a difference in toxicity. That does not mean that ALK inhibitors such as crizotinib do not have a place in upfront therapy. Clinical trials will need to determine how they are used a...